Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 10 FEBRUARY 2025

CN Final Antimonopoly Guidelines For The Pharmaceutical Sector

Toby Mak
Explore more from Toby Mak

Thanks for the notification from Aaron Wininger of Schwegman Lundberg & Woessner, P.A. , the China State Administration for Market Regulation SAMR announced the finalized...

ChinaIntellectual Property
Toby Mak
Toby Mak

Thanks for the notification from Aaron Wininger of Schwegman Lundberg & Woessner, P.A. , the China State Administration for Market Regulation SAMR announced the finalized antimonopoly guidelines for the pharmaceutical sector at the link below:

https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fldzfys/art/2025/art_4f615267290d443f9b4e571774ed3d2a.html

These guidelines were announced on 23 January 2025, and then became immediate effective.

The draft was announced in August 2024, and was reported in my article below:

https://www.linkedin.com/pulse/cn-samr-antitrust-guidelines-pharmaceutical-sector-draft-toby-mak-bk1vc/

I have compared the August 2024 draft the final version, and note the following important (in my view) changes (in below, unless otherwise specified, the article numbers refer to those in the final guidelines):

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

China's Supreme Court Issues Landmark Judicial Rules On AI: Implications For Product Liability, IP, Data, And Generative AI

China's Supreme People's Court has issued comprehensive judicial rules addressing artificial intelligence disputes, establishing frameworks for product liability, intellectual property rights, and data protection. These landmark opinions provide critical guidance for global companies navigating AI-related legal risks in China's evolving regulatory landscape.
ChinaIntellectual Property
Jones Day
Jones Day